This statistic shows the probability of phase III success for new drugs in the U.S., in the period from January 1, 2011, to November 30, 2020, by disease area. It was found that drugs in hematology had the highest phase III success rates.
The probability of phase III success for new drugs in select disease areas in the U.S. between 2011 and 2020
Adjust the presentation of the statistic and data points.
Share the statistic on social media channels or embed the statistic in your
website using "Embed Code", where available.
Cite this statistic and select one of the following formats: APA, Chicago, Harvard, MLA & Bluebook.
Print the statistic including description and metadata.
Chart type
The probability of phase III success for new drugs in select disease areas in the U.S. between 2011 and 2020
Share this statistic
You have no right to use this feature.
Make sure to contact us if you are interested in scientific citation.
You can upgrade your account to enable this functionality for all statistics.
This feature is not available with your current account.Request access
Only company-sponsored, FDA registration-enabling development
programs were included in this analysis. Investigator-sponsored studies and combinations with other
investigational drugs were excluded.
Learn more about how Statista can support your business.
Biotechnology Innovation Organization, & Pharma Intelligence, & QLS Advisors. (February 26, 2021). The probability of phase III success for new drugs in select disease areas in the U.S. between 2011 and 2020 [Graph]. In Statista. Retrieved April 29, 2025, from https://www.statista.com/statistics/597742/drug-development-phase-three-probability-of-success/
Biotechnology Innovation Organization, und Pharma Intelligence, und QLS Advisors. "The probability of phase III success for new drugs in select disease areas in the U.S. between 2011 and 2020." Chart. February 26, 2021. Statista. Accessed April 29, 2025. https://www.statista.com/statistics/597742/drug-development-phase-three-probability-of-success/
Biotechnology Innovation Organization, Pharma Intelligence, QLS Advisors. (2021). The probability of phase III success for new drugs in select disease areas in the U.S. between 2011 and 2020. Statista. Statista Inc.. Accessed: April 29, 2025. https://www.statista.com/statistics/597742/drug-development-phase-three-probability-of-success/
Biotechnology Innovation Organization, and Pharma Intelligence, and QLS Advisors. "The Probability of Phase Iii Success for New Drugs in Select Disease Areas in The U.S. between 2011 and 2020." Statista, Statista Inc., 26 Feb 2021, https://www.statista.com/statistics/597742/drug-development-phase-three-probability-of-success/
Biotechnology Innovation Organization & Pharma Intelligence & QLS Advisors, The probability of phase III success for new drugs in select disease areas in the U.S. between 2011 and 2020 Statista, https://www.statista.com/statistics/597742/drug-development-phase-three-probability-of-success/ (last visited April 29, 2025)
The probability of phase III success for new drugs in select disease areas in the U.S. between 2011 and 2020 [Graph], Biotechnology Innovation Organization, & Pharma Intelligence, & QLS Advisors, February 26, 2021. [Online]. Available: https://www.statista.com/statistics/597742/drug-development-phase-three-probability-of-success/
Profit from additional features with an Employee Account
Please create an employee account to be able to mark statistics as favorites.
Then you can access your favorite statistics via the star in the header.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
